title: Drug therapy for treating post-dural puncture headache.
abstract: BACKGROUND
  Post-dural puncture headache (PDPH) is the most common complication of lumbar puncture, an invasive procedure frequently performed in the emergency room. Numerous pharmaceutical drugs have been proposed to treat PDPH but there are still some uncertainties about their clinical effectiveness.
  
  
  OBJECTIVE
  To assess the effectiveness and safety of drugs for treating PDPH in adults and children.
  
  
  METHODS
  The search strategy included the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2011, Issue 2), MEDLINE (from 1950 to June 2011), EMBASE (from 1980 to June 2011) and CINAHL (from 1982 to June 2011). There was no language restriction.
  
  
  METHODS
  We considered randomised controlled trials (RCTs) assessing the effectiveness of any pharmacological drug used for treating PDPH.
  
  
  METHODS
  Review authors independently selected studies, assessed risks of bias and extracted data. We estimated risk ratios (RR) for dichotomous data and mean differences (MD) for continuous outcomes. We calculated a 95% confidence interval (CI) for each RR and MD. We did not undertake meta-analysis because the included studies assessed different sorts of drugs or different outcomes. We performed an intention-to-treat (ITT) analysis.
  
  
  RESULTS
  We included seven RCTs (200 participants) in this review (between 88% and 90.5% were women; mostly parturients (84% to 87%) after a lumbar puncture for a regional anaesthesia). Pharmacological drugs assessed were oral and intravenous caffeine, subcutaneous sumatriptan, oral gabapentin, oral theophylline, intravenous hydrocortisone and intramuscular adrenocorticotropic hormone (ACTH).One RCT reported data about PDPH persistence of any severity at follow up (primary outcome); caffeine reduced the number of participants with PDPH at one to two hours when compared to placebo. Treatment with caffeine also decreased the need for a conservative supplementary therapeutic option. Treatment with gabapentin versus placebo reported better visual analogue scale (VAS) scores after one, two, three and four days; treatment with hydrocortisone plus conventional treatment showed better VAS scores than conventional treatment alone at six, 24 and 48 hours and treatment with theophylline showed a lower mean "sum of pain" when compared with placebo. Sumatriptan and ACTH did not show any relevant effect for this outcome.There were no clinically significant drug adverse events.The rest of the outcomes were not reported by the RCTs or did not show any relevant effect.
  
  
  CONCLUSIONS
  Caffeine has shown effectiveness for treating PDPH, decreasing the proportion of participants with PDPH persistence and those requiring supplementary interventions, when compared with placebo. Gabapentin, theophylline and hydrocortisone have also shown a decrease in pain severity scores when compared with placebo or conventional care.There is a lack of conclusive evidence for the other drugs assessed (sumatriptan and ACTH).These conclusions should be interpreted with caution, due to the lack of information to allow correct appraisal of risk of bias, the small sample sizes of studies and also the limited generalisability, as most participants were post-partum women in their 30s.
authors.affiliation: Emergency Department, Hospital de Figueres, Fundació Salut Empordà, Rda Rector Aroles s/n, Figueres, Girona-Catalunya, Spain, 17600.
authors.forename: Xavier
authors.initials: X
authors.lastname: Basurto Ona
authors.forename: Laura
authors.initials: L
authors.lastname: Martínez García
authors.forename: Ivan
authors.initials: I
authors.lastname: Solà
authors.forename: Xavier
authors.initials: X
authors.lastname: Bonfill Cosp
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D002110:Caffeine / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005260:Female; D000077206:Gabapentin; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008297:Male; D010147:Pain Measurement / Q000379:methods; D051299:Post-Dural Puncture Headache / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013129:Spinal Puncture / Q000009:adverse effects*; D018170:Sumatriptan / Q000627:therapeutic use; D013806:Theophylline / Q000627:therapeutic use; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D002110:Caffeine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D018170:Sumatriptan; D000324:Adrenocorticotropic Hormone; D013806:Theophylline; D006854:Hydrocortisone